\chapter{Clinical Findings \& Medical History}
\label{app:clinical-findings}

This appendix documents objective clinical data, laboratory findings, and medical history. For symptom descriptions, see Appendix~\ref{app:personal-symptoms}. For current management protocols, see Appendix~\ref{app:medical-management}.

% DOCUMENTED CLINICAL FINDINGS
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

\section{Documented Clinical Findings}
\label{sec:documented-findings}

This section records objective clinical data from medical records, laboratory tests, and specialist evaluations.

\subsection{Laboratory Findings (2025)}
\label{subsec:lab-findings-2025}

\subsubsection{Hematology and Iron Status}

\begin{table}[htbp]
\centering
\caption{Iron Status and Hematology (2025)}
\label{tab:iron-status}
\begin{tabular}{lccl}
\toprule
\textbf{Parameter} & \textbf{Result} & \textbf{Reference} & \textbf{Clinical Note} \\
\midrule
Hemoglobin & 15.6 g/dL & 13.5--17.6 & Normal \\
Ferritin & 40--55 $\mu$g/L & 20--300 & \textbf{Suboptimal for ME/CFS} \\
Iron & 107 $\mu$g/dL & 65--175 & Normal \\
Transferrin & 3.12 g/L & 1.74--3.64 & Normal \\
Transferrin saturation & 25\% & 15--50 & Normal \\
Vitamin B12 & 383--424 ng/L & 187--883 & Normal \\
Folate & 2.8--4.2 $\mu$g/L & 2.3--17.6 & Low-normal \\
\bottomrule
\end{tabular}
\end{table}

\paragraph{Ferritin Interpretation.}
While ferritin 40--55 $\mu$g/L falls within the standard reference range, K.\ Collet (somnologist, Clinique Saint-Luc Bouge, November 2021) specifically noted: \emph{``Un taux supérieur à 70--75 $\mu$g/L est recommandé''} in the context of periodic limb movements during sleep. This target is also recommended for ME/CFS patients given iron's role in:
\begin{itemize}
    \item Dopamine synthesis (tyrosine hydroxylase cofactor)
    \item Mitochondrial electron transport chain (cytochromes)
    \item Restless legs syndrome management
\end{itemize}

\subsubsection{Immune and Inflammatory Markers}

\begin{table}[htbp]
\centering
\caption{Immune Markers (October--November 2025)}
\label{tab:immune-markers}
\begin{tabular}{lccl}
\toprule
\textbf{Parameter} & \textbf{Result} & \textbf{Reference} & \textbf{Clinical Note} \\
\midrule
\multicolumn{4}{l}{\textit{Rheumatoid markers}} \\
Rheumatoid Factor & 119--176 IU/mL & $<$14--20 & \textbf{Strongly positive} \\
Anti-CCP & $<$0.8 U/mL & $<$7 & Negative \\
ANA & Negative & $<$1/80 & Normal \\
\midrule
\multicolumn{4}{l}{\textit{Inflammation}} \\
CRP & 1.6--3.6 mg/L & $<$5--8.5 & Normal \\
\midrule
\multicolumn{4}{l}{\textit{Complement}} \\
C3 & 1.39--1.49 g/L & 0.82--1.85 & Normal \\
C4 & 0.39--0.42 g/L & 0.10--0.53 & Upper normal \\
\midrule
\multicolumn{4}{l}{\textit{Immunoglobulins}} \\
IgG & 14.4 g/L & 5.40--18.22 & Normal \\
IgA & 2.80 g/L & 0.63--4.84 & Normal \\
IgM & 0.95 g/L & 0.22--2.40 & Normal \\
\bottomrule
\end{tabular}
\end{table}

\paragraph{Rheumatoid Factor Interpretation.}
The strongly elevated RF (119--176 IU/mL) with \textbf{negative} Anti-CCP effectively rules out rheumatoid arthritis. Elevated RF without Anti-CCP occurs in:
\begin{itemize}
    \item Chronic infections (including post-viral states)
    \item Other autoimmune conditions
    \item ME/CFS (non-specific immune activation)
    \item Healthy individuals (false positive, especially older adults)
\end{itemize}
The negative ANA further argues against systemic autoimmune disease.

\subsubsection{Viral Serology}

\begin{table}[htbp]
\centering
\caption{Viral Serology (October 2025)}
\label{tab:viral-serology}
\begin{tabular}{lccl}
\toprule
\textbf{Virus} & \textbf{IgG} & \textbf{IgM} & \textbf{Interpretation} \\
\midrule
EBV (VCA) & $>$750 U/mL & Negative & Past infection, very high titer \\
Parvovirus B19 & 61.0 U/mL & Negative & Past infection \\
CMV & 0.9 U/mL & Negative & No exposure \\
Hepatitis B & Negative & --- & No infection/immunity \\
Hepatitis C & Negative & --- & No infection \\
Toxoplasmosis & $<$0.5 UI/mL & Negative & No exposure \\
Borrelia (Lyme) & 6.7 U/mL & Negative & No infection \\
Bartonella & 1/64 & Negative & At detection threshold \\
\bottomrule
\end{tabular}
\end{table}

\paragraph{EBV Interpretation.}
The very high EBV VCA IgG ($>$750 U/mL) indicates past EBV infection with robust antibody response. EBV is one of the most common triggers for ME/CFS. The high titer suggests either:
\begin{itemize}
    \item Strong initial immune response to past infection
    \item Possible ongoing low-level viral reactivation
    \item Persistent immune stimulation from EBV antigens
\end{itemize}
This finding supports the post-infectious etiology model for ME/CFS.

\subsubsection{Metabolic Panel}

\begin{table}[htbp]
\centering
\caption{Metabolic Parameters (2025)}
\label{tab:metabolic-panel}
\begin{tabular}{lccl}
\toprule
\textbf{Parameter} & \textbf{Result} & \textbf{Reference} & \textbf{Clinical Note} \\
\midrule
\multicolumn{4}{l}{\textit{Glucose metabolism}} \\
Fasting glucose & 104 mg/dL & 70--100 & Impaired fasting glucose \\
\midrule
\multicolumn{4}{l}{\textit{Lipids}} \\
Total cholesterol & 202--208 mg/dL & $<$190 & Elevated \\
LDL cholesterol & 132--137 mg/dL & $<$100 & Elevated \\
HDL cholesterol & 42--49 mg/dL & $>$40 & Low-normal \\
Triglycerides & 117--135 mg/dL & 40--150 & Normal \\
\midrule
\multicolumn{4}{l}{\textit{Liver}} \\
Total bilirubin & 1.52 mg/dL & 0.2--1.2 & Elevated (indirect) \\
Direct bilirubin & 0.45 mg/dL & 0--0.5 & Normal \\
AST/ALT & 31/40 U/L & 5--34/$<$55 & Normal \\
GGT & 23--26 U/L & 11--59 & Normal \\
\midrule
\multicolumn{4}{l}{\textit{Renal}} \\
Creatinine & 1.09--1.10 mg/dL & 0.72--1.25 & Normal \\
eGFR (EKFC) & 81--82 mL/min & 59--137 & Normal \\
\bottomrule
\end{tabular}
\end{table}

\paragraph{Fasting Glucose Interpretation.}
Fasting glucose of 104 mg/dL falls in the ``impaired fasting glucose'' range (100--125 mg/dL). In the context of ME/CFS, this may reflect:
\begin{itemize}
    \item Mitochondrial dysfunction affecting glucose metabolism
    \item Metabolic ``safe mode'' with altered fuel utilization
    \item Stress response/cortisol effects
    \item True early insulin resistance
\end{itemize}
Recommend HbA1c testing to assess longer-term glucose control.

\paragraph{Bilirubin Interpretation.}
Elevated total bilirubin (1.52 mg/dL) with normal direct bilirubin and liver enzymes suggests unconjugated hyperbilirubinemia. While this pattern is consistent with Gilbert syndrome, \textbf{no clinical symptoms have been observed}. This finding is of uncertain clinical significance and does not require treatment.

\subsubsection{Hormonal and Nutritional Status}

\begin{table}[htbp]
\centering
\caption{Hormonal and Nutritional Parameters (2025)}
\label{tab:hormonal-nutritional}
\begin{tabular}{lccl}
\toprule
\textbf{Parameter} & \textbf{Result} & \textbf{Reference} & \textbf{Clinical Note} \\
\midrule
\multicolumn{4}{l}{\textit{Thyroid}} \\
TSH & 2.10--2.51 mU/L & 0.3--4.2 & Normal \\
Free T4 & 11.6 pmol/L & 10.3--20.6 & Normal \\
\midrule
\multicolumn{4}{l}{\textit{Adrenal}} \\
Cortisol (morning) & 6.3 $\mu$g/dL & 7--25 & \textbf{Low-normal} \\
\midrule
\multicolumn{4}{l}{\textit{Gonadal}} \\
Testosterone & 469 ng/dL & 240--870 & Normal \\
\midrule
\multicolumn{4}{l}{\textit{Vitamins/Minerals}} \\
Vitamin D (25-OH) & 27--42 $\mu$g/L & 30--60 & Improved (was deficient) \\
Selenium & 78 $\mu$g/L & 60--120 & \textbf{Suboptimal} (rec.\ 90--143) \\
Zinc & 106 $\mu$g/dL & 60--130 & Suboptimal (rec.\ $>$110) \\
Calcium & 2.60 mmol/L & 2.10--2.55 & Slightly elevated \\
Magnesium & 0.92 mmol/L & 0.66--1.07 & Normal \\
\bottomrule
\end{tabular}
\end{table}

\paragraph{Cortisol Interpretation.}
Morning cortisol of 6.3 $\mu$g/dL is at the low end of the reference range (7--25 for morning). In ME/CFS, blunted cortisol awakening response and low-normal cortisol are common findings reflecting HPA axis dysfunction. This may contribute to:
\begin{itemize}
    \item Morning fatigue and difficulty waking
    \item Reduced stress tolerance
    \item Impaired inflammatory regulation
\end{itemize}

\subsubsection{Allergy Panel}

\begin{table}[htbp]
\centering
\caption{Allergy Testing (August 2025)}
\label{tab:allergy-panel}
\begin{tabular}{lcc}
\toprule
\textbf{Allergen Panel} & \textbf{Result (kUA/L)} & \textbf{Interpretation} \\
\midrule
Total IgE & 63 kU/L & Normal ($<$114) \\
Trees TX5 (alder, hazel, elm, willow, poplar) & 1.60 & Positive \\
Trees TX6 (maple, birch, beech, oak, walnut) & 2.11 & Positive \\
Grasses GX3 & 8.89 & \textbf{Strongly positive} \\
Feathers EX71 & $<$0.10 & Negative \\
Nuts FX1 (peanut, hazelnut, Brazil, almond, coconut) & 3.33 & Positive \\
Cat epithelium & $<$0.10 & Negative \\
Soy IgG & 88 mg/L & \textbf{Elevated} (ref $<$5) \\
\bottomrule
\end{tabular}
\end{table}

\subsection{Polysomnography Findings (December 2018)}
\label{subsec:psg-findings}

Full polysomnography with Multiple Sleep Latency Test (MSLT) performed at CHA Libramont, Sleep Laboratory, analyzed by Dr.\ Stéphane Noël. Date: 07--08/12/2018.

\subsubsection{Patient Characteristics at Time of Study}

\begin{itemize}
    \item Age: 37 years
    \item Weight: 72 kg; Height: 175 cm; BMI: 23.5
    \item Chief complaint: \emph{``Fatigue présente depuis l'adolescence''} (fatigue since adolescence)
    \item No caffeine, no tobacco, no alcohol
    \item Physical activity: Swimming 4$\times$/week
    \item Chronotype: Evening type
    \item Sleep need: 8 hours + 1.5-hour nap
    \item Recently stopped Concerta (July 2018), gained 4 kg in 3 months
\end{itemize}

\subsubsection{Questionnaire Scores}

\begin{table}[htbp]
\centering
\caption{Sleep Questionnaire Results (2018 and 2021)}
\label{tab:sleep-questionnaires}
\begin{tabular}{lccc}
\toprule
\textbf{Scale} & \textbf{2018} & \textbf{2021} & \textbf{Interpretation} \\
\midrule
Epworth Sleepiness Scale & 16/24 & 14/24 & Pathological ($>$10) \\
Fatigue Severity Score & 4.5 & --- & Abnormal fatigue \\
Pichot Depression & --- & 10/13 & Mood disorder suggested \\
Goldberg Anxiety & --- & 6/7 & Anxiety disorder suggested \\
Insomnia Severity Index & --- & 18/28 & Moderate (16 pts daytime) \\
\bottomrule
\end{tabular}
\end{table}

\subsubsection{Nocturnal Polysomnography Results}

\begin{table}[htbp]
\centering
\caption{Polysomnography Parameters (December 2018)}
\label{tab:psg-results}
\begin{tabular}{lccc}
\toprule
\textbf{Parameter} & \textbf{Result} & \textbf{Normal} & \textbf{Assessment} \\
\midrule
\multicolumn{4}{l}{\textit{Sleep Duration}} \\
Time in bed & 518 min & --- & --- \\
Total sleep time (TST) & 429 min & --- & Normal \\
Sleep period & 515 min & --- & --- \\
\midrule
\multicolumn{4}{l}{\textit{Sleep Quality Indices}} \\
Sleep efficiency (TST/TRS) & 82.8\% & $>$86\% & \textbf{Reduced} \\
Sleep continuity (TST/TPS) & 83.3\% & $>$95\% & \textbf{Insufficient} \\
Sleep quality index (SWS+REM/TST) & 54.9\% & $>$35\% & Good \\
\midrule
\multicolumn{4}{l}{\textit{Sleep Architecture}} \\
N1 (light sleep) & 2 min (0.5\%) & 2--5\% & Low \\
N2 (intermediate) & 191 min (44.6\%) & 45--55\% & Normal \\
N3 (deep/SWS) & 141 min (32.8\%) & 15--33\% & Normal-high \\
REM sleep & 95 min (22.1\%) & 20--25\% & Normal \\
\midrule
\multicolumn{4}{l}{\textit{Sleep Fragmentation}} \\
Stage changes & 131 & --- & \textbf{Elevated} \\
WASO (wake after sleep onset) & 86 min & $<$30 min & \textbf{Excessive} \\
Number of awakenings & 25/night & --- & Elevated \\
Micro-arousal index & 6.1/h & $<$10/h & Normal \\
\midrule
\multicolumn{4}{l}{\textit{Sleep Latencies}} \\
Sleep onset latency & 13 min & $<$30 min & Normal \\
REM latency & 72 min & 70--120 min & Normal \\
\bottomrule
\end{tabular}
\end{table}

\subsubsection{Periodic Limb Movements}

\begin{table}[htbp]
\centering
\caption{Periodic Limb Movement Analysis}
\label{tab:plm-analysis}
\begin{tabular}{lcc}
\toprule
\textbf{Parameter} & \textbf{Result} & \textbf{Normal} \\
\midrule
PLM index (during sleep) & 13.3/h & $<$5/h \\
PLM index (during N1) & 30.0/h & --- \\
PLM index (during N2) & 10.7/h & --- \\
PLM index (during N3) & 11.9/h & --- \\
PLM duration (mean) & 10.2 sec & --- \\
\bottomrule
\end{tabular}
\end{table}

\paragraph{PLM Interpretation.}
The PLM index of 13.3/h is elevated (normal $<$5/h) and contributes to sleep fragmentation. K.\ Collet (2021) specifically noted that ferritin $>$70--75 $\mu$g/L is recommended for patients with periodic limb movements.

\subsubsection{Respiratory Events}

\begin{table}[htbp]
\centering
\caption{Respiratory Analysis}
\label{tab:respiratory-analysis}
\begin{tabular}{lcc}
\toprule
\textbf{Parameter} & \textbf{Result} & \textbf{Interpretation} \\
\midrule
Apnea-Hypopnea Index (AHI) & 3.8/h & Normal ($<$5/h) \\
AHI in REM & 9.5/h & Mild \\
AHI supine & 7.7/h & Mild positional \\
Central apneas & 4 events & Minimal \\
Obstructive apneas & 3 events & Minimal \\
Obstructive hypopneas & 24 events & Predominant type \\
Mean SpO$_2$ & 95.9\% & Normal \\
Time SpO$_2$ $<$90\% & 0 min & Normal \\
\bottomrule
\end{tabular}
\end{table}

\paragraph{Respiratory Interpretation.}
Overall AHI is within normal limits. The study concluded: \emph{``L'analyse de la respiration ne met pas en évidence d'apnées, d'hypopnées ou de désaturation.''} Respiratory events are not the primary cause of sleep disruption.

\subsubsection{Multiple Sleep Latency Test (MSLT)}

\begin{table}[htbp]
\centering
\caption{MSLT Results (December 2018)}
\label{tab:mslt-results}
\begin{tabular}{lcccl}
\toprule
\textbf{Nap Time} & \textbf{Sleep Latency} & \textbf{Stages Reached} & \textbf{SOREMP} & \textbf{Note} \\
\midrule
09:00 & 0.5 min & N1, N2, N3 & No & Extremely rapid \\
11:00 & 3.0 min & N1, N2, N3 & No & Rapid \\
13:00 & 12.0 min & N1, N2 & No & Normal \\
15:00 & No sleep & --- & No & Did not fall asleep \\
\midrule
\textbf{Mean latency} & \textbf{9.0 min} & --- & \textbf{0/4} & \textbf{Pathological} \\
\bottomrule
\end{tabular}
\end{table}

\paragraph{MSLT Interpretation.}
\begin{itemize}
    \item Mean sleep latency of 9 minutes is pathological ($<$10 min indicates excessive daytime sleepiness)
    \item Absence of sleep-onset REM periods (SOREMPs) rules out narcolepsy
    \item Pattern shows \textbf{morning-predominant somnolence}---fell asleep in 30 seconds at 9h, 3 minutes at 11h
    \item Afternoon improvement (12 min at 13h, no sleep at 15h)
\end{itemize}

Report conclusion: \emph{``Présence de somnolence pathologique essentiellement en matinée (endormissement rapide et présence de sommeil lent profond).''}

\subsubsection{Official Diagnosis (2018 Sleep Study)}

\begin{tcolorbox}[colback=gray!5!white,colframe=gray!75!black,title=Polysomnography Diagnosis]
\textbf{Dyssomnia} characterized by:
\begin{itemize}
    \item Sleep fragmentation
    \item High number of stage changes (131)
    \item Periodic limb movements during sleep (index 13.3/h)
    \item No significant respiratory events
\end{itemize}

\textbf{Excessive daytime somnolence} (Epworth 16/24) with:
\begin{itemize}
    \item Risk of falling asleep while driving
    \item Pathological MSLT (mean latency 9 min)
    \item Morning-predominant pattern
    \item No narcolepsy features (no SOREMPs)
\end{itemize}

\textbf{Abnormal fatigue complaint} (Fatigue Severity Score 4.5)
\end{tcolorbox}

\subsection{Kevin Collet Assessment (November 2021)}
\label{subsec:collet-assessment}

Sleep pathology consultation at Clinique Saint-Luc Bouge, 04/11/2021.

\subsubsection{Key Clinical Observations}

\begin{itemize}
    \item \textbf{Fatigue onset}: Age 15--16 years (adolescence)
    \item \textbf{Fatigue pattern}: Fluctuating, with phases of 6--10 days of extreme physical and mental fatigue, headaches, brain fog, irritability
    \item \textbf{Burnout}: End of 2017
    \item \textbf{Family history}: Mother and two sisters diagnosed with ADHD
    \item \textbf{Cognitive}: IQ $>$135, skipped 6th grade primary, excellent academic facility
    \item \textbf{Weight}: 74 kg at 173 cm (BMI 24.7)---5--6 kg gain over 3 years
\end{itemize}

\subsubsection{Collet Conclusion}

\begin{quote}
\emph{``Votre patient présente un tableau complexe de fatigue chronique d'étiologie indéterminée. Le bilan du sommeil réalisé au CHA n'a pas été décisif quant à un trouble du sommeil spécifique. L'hypersomnie idiopathique suspectée est un trouble se caractérisant par un allongement anormal du temps de sommeil avec persistance de fatigue/somnolence durant les phases d'éveil.''}

---K.\ Collet, Somnologist, November 2021
\end{quote}

\subsubsection{Recommendations from Collet Report}

\begin{enumerate}
    \item Ferritin target: $>$70--75 $\mu$g/L for PLM management
    \item Consider complete hypersomnia re-evaluation (actigraphy + PSG + MSLT + bedrest)
    \item ADHD/HP evaluation suggested (Dr.\ Linsmeaux, ADHD clinic)
    \item Continued Provigil treatment (100 mg $\times$3/day)
\end{enumerate}

\subsection{Disease Evolution Timeline}
\label{subsec:disease-timeline}

This subsection documents major milestones, changes in severity, and significant events in the disease course.

\begin{description}
    \item[Constitutional Phase (Childhood--2017):] Lifelong fatigue, idiopathic hypersomnia
    \begin{itemize}
        \item Early childhood: Required afternoon naps through age 7--8
        \item \textbf{Adolescence (age $\sim$13--15):} Onset of recurrent brain fog; constant tiredness but maintained academic performance
        \item \textbf{Age $\sim$20 (circa 2001):} Onset of spontaneous muscle cramps (nocturnal, throat/neck, without exertion)
        \item Young adulthood: University difficulties despite high IQ (>135) - cognitive impairment from energy deficit, not intellectual limitation
        \item \textbf{Work years:} Barely maintaining employment through unsustainable compensatory strategies
        \begin{itemize}
            \item Spent entire Saturdays sleeping (morning + afternoon) to recover for evening table tennis matches (not for work week)
            \item Experienced mid-match energy collapse leading to performance decline and losses
            \item Already too exhausted for proper work engagement during the week; just going through the motions
            \item Progressive difficulty maintaining even this unsustainable level of compensatory effort
            \item Employment was survival mode, not functional work performance
        \end{itemize}
        \item \textbf{Historical exercise tolerance:} At some point could swim 1\,km daily
        \begin{itemize}
            \item Physical fitness improved (better table tennis performance)
            \item Cognitive symptoms (fog, sleepiness) persisted during the day
            \item Exercise provided net benefit despite not eliminating underlying dysfunction
        \end{itemize}
        \item Status: Severely impaired but maintaining employment through extreme, unsustainable compensatory effort; already too exhausted for normal social/work engagement
    \end{itemize}

    \item[Triggering Event (Late 2017):] Severe burnout
    \begin{itemize}
        \item Burnout documented end of 2017 (per K.\ Collet report, November 2021)
        \item Likely precipitated transition to full ME/CFS phenotype
        \item Burnout involves HPA axis dysregulation, cortisol dysfunction
        \item May have ``locked'' the metabolic safe mode described in speculative hypotheses
    \end{itemize}

    \item[Post-Trigger Phase (2018--Present):] Severe ME/CFS with disabling PEM
    \begin{itemize}
        \item \textbf{Important:} PEM itself is not new---it has been present for decades (weekend crash-recovery cycles, mid-match collapses)
        \item What changed: \textbf{Severity escalation} from ``manageable with extreme effort'' to ``disabling''
        \item \textbf{29 June 2018:} Concussion (commotion cérébrale) --- Clinique Saint-Joseph, Arlon
        \begin{itemize}
            \item \textbf{Mechanism}: Vagal syncope in public place $\rightarrow$ fall from chair $\rightarrow$ head trauma
            \item \textbf{Post-traumatic amnesia}: 5 hours (significant)
            \item \textbf{Clinical note}: ``Syncopes répétées'' (recurrent syncopes) --- not an isolated event
            \item \textbf{Imaging}: CT crâne + cervical: negative for post-traumatic lesions
            \item \textbf{Diagnosis}: ``Commotion cérébrale très probable'' (Dr.\ Mangbau)
            \item \textbf{Follow-up ordered}: EEG (2/7/2018), Holter monitoring (16/7/2018)
            \item \textbf{Treatment}: Litican (piracetam --- nootropic for post-TBI cognitive support)
            \item \textbf{Relevant lab findings at admission}:
            \begin{itemize}
                \item Lactic acid: \textbf{3.18 mmol/L} (ref.\ 0.50--2.20) --- elevated at baseline
                \item CPK: \textbf{254 U/L} (ref.\ 5--195) --- muscle damage marker elevated
                \item LDH: \textbf{249 U/L} (ref.\ 135--225) --- upper limit
                \item Prolactin: \textbf{93.3 $\mu$g/L} (ref.\ 4.0--15.2) --- markedly elevated (post-ictal?)
                \item Glucose: 148 mg/dL (ref.\ 70--105) --- elevated (stress response)
            \end{itemize}
            \item \textbf{ME/CFS relevance}:
            \begin{itemize}
                \item Elevated baseline lactic acid supports metabolic dysfunction hypothesis
                \item Recurrent vagal syncopes consistent with dysautonomia
                \item Post-concussion syndrome shares features with ME/CFS: cognitive dysfunction, fatigue, exercise intolerance
                \item TBI can trigger or exacerbate neuroimmune dysfunction
                \item Timeline: 6 months after burnout trigger, during early deterioration phase
            \end{itemize}
        \end{itemize}
        \item Transition from ``tired but functional with compensatory strategies'' to ``unable to compensate''
        \item Unable to maintain employment consistently
        \item \textbf{2025/2026:} Attempted to resume swimming regimen (4--5 months duration)
        \begin{itemize}
            \item Previously: 1\,km daily swimming improved physical fitness (despite persistent cognitive symptoms)
            \item Current attempt: Resulted in \textbf{constant mental fog} severe enough to eliminate work function
            \item Consequence: Work underperformance leading to job loss
            \item Demonstrates disease progression: exercise changed from ``net benefit with symptoms'' to ``disabling cognitive PEM outweighing any fitness gains''
        \end{itemize}
        \item Current functional status: Severe functional impairment despite preserved basic mobility
        \begin{itemize}
            \item \textit{Can perform}: Drive children to school, buy groceries, sit at computer on better days
            \item \textit{Requires stimulants}: For any function; without stimulants, completely non-functional
            \item \textit{Profound exhaustion}: Despite stimulants, too tired for social engagement, eye contact, smiling, laughing
            \item \textit{Isolation preference}: Human interaction requires energy that doesn't exist; prefer distance over engagement
            \item \textit{Summary}: Can execute essential tasks but no energy for anything that makes life meaningful; ``too tired to be human''
        \end{itemize}
    \end{itemize}

    \item[Diagnoses:]
    \begin{itemize}
        \item Idiopathic hypersomnia (sleep study confirmed)
        \item Restless legs syndrome
        \item Sleep apnea (some degree)
        \item ME/CFS features: PEM, cognitive dysfunction, unrefreshing sleep
    \end{itemize}

    \item[Treatment milestones:]
    \begin{itemize}
        \item Methylphenidate (Rilatine): Effective for arousal/function
        \item Modafinil (Provigil): Effective for wakefulness
        \item LDN: Current status and effect to be documented
    \end{itemize}

    \item[Functional status changes:]
    \begin{itemize}
        \item Pre-2018: Maintaining employment through unsustainable effort; already too exhausted for proper work engagement; required extreme weekend recovery (full-day Saturday sleep)
        \item Post-2018: Unable to maintain employment consistently
        \item 2025/2026: Job loss following exercise-induced cognitive PEM (swimming regimen)
        \item Current (2026): Severe impairment; can perform essential tasks (drive, groceries, limited computer work) but too exhausted for social engagement or meaningful activities despite stimulants
    \end{itemize}
\end{description}

\subsection{Medication History}
\label{subsec:medication-history}

\begin{table}[htbp]
\centering
\caption{Medication History Log}
\label{tab:medication-history}
\begin{tabular}{lllp{4cm}}
\toprule
\textbf{Medication} & \textbf{Started} & \textbf{Stopped} & \textbf{Notes} \\
\midrule
LDN 3\,mg & 2026-01-05 & ongoing & Morning dosing (atypical); rapid escalation from starting dose due to good tolerance; plan to increase to 4--4.5\,mg pending prescription \\
Methylphenidate MR 30\,mg & & ongoing & 1--2 doses daily, max 3 pills total with modafinil \\
Modafinil 100\,mg & & ongoing & 1--2 doses daily, max 3 pills total with methylphenidate \\
% Add rows as needed
\bottomrule
\end{tabular}
\end{table}

\subsection{Supplement Trial Log}
\label{subsec:supplement-log}

\begin{table}[htbp]
\centering
\caption{Supplement Trial History}
\label{tab:supplement-history}
\begin{tabular}{llllp{3.5cm}}
\toprule
\textbf{Supplement} & \textbf{Dose} & \textbf{Started} & \textbf{Stopped} & \textbf{Effect/Notes} \\
\midrule
Acetyl-L-carnitine (Bandini) & 1000\,mg & 2026-01-21 & ongoing & Targets carnitine shuttle dysfunction for both muscle cramps and cognitive fog; monitor for GI effects \\
Riboflavin (B2) & 400\,mg & 2026-01-21 & ongoing & Migraine prevention (4--12 week timeline); supports FAD production for mitochondrial function; take separate from methylphenidate \\
Magnesium glycinate & 300--400\,mg & 2026-01-21 & ongoing & Replaces Magnecaps Dynatonic to avoid methylphenidate interaction; bedtime dosing for cramps; separate from methylphenidate by 2--4 hours \\
% CoQ10 (Ubiquinol) & 100\,mg & & & \\
\bottomrule
\end{tabular}
\end{table}

\subsection{Pattern Recognition Notes}
\label{subsec:pattern-notes}

Use this section to document observed patterns, correlations, and insights derived from the journal entries.

\paragraph{Identified Triggers.}
\begin{itemize}
    \item % E.g., "Standing >15 min triggers air hunger within 2 hours"
    \item % E.g., "Cognitive work >2 hours leads to next-day crash"
\end{itemize}

\paragraph{Helpful Interventions.}
\begin{itemize}
    \item % E.g., "Horizontal rest with legs elevated reduces leg exhaustion"
    \item % E.g., "Electrolytes before activity delays onset of symptoms"
\end{itemize}

\paragraph{Medication Observations.}
\begin{itemize}
    \item % E.g., "Methylphenidate masks fatigue—HR monitor essential"
    \item % E.g., "LDN best taken at night; morning dosing disrupts sleep"
\end{itemize}

\paragraph{Seasonal/Cyclical Patterns.}
\begin{itemize}
    \item % E.g., "Symptoms worse in winter months"
    \item % E.g., "Menstrual cycle correlation: worse days X-Y"
\end{itemize}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
